Vaccine may cure chronic myeloid leukemia CML


Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

Gleevec, one of the first targeted cancer therapies with wide success in CML patients, destroys most leukemic cells in the body, but in most patients, some cancerous cells remain and are measurable with sensitive molecular tests. These remaining cells are a source of relapse, according to the investigators, especially if Gleevec therapy is stopped.

In a pilot study published in Clinical Cancer Research, the Johns Hopkins investigators used a vaccine made from CML cells irradiated to halt their cancerous potential and genetically altered to produce an immune system stimulator called GM-CSF. The treated cells also carry molecules, called antigens, specific to CML cells, which prime the immune system to recognize and kill circulating CML cells.

The study vaccine was given to 19 CML patients with measurable cancer cells, despite taking Gleevec for at least one year. A series of 10 skin injections were given every three weeks for a total of four times. After a median of 72 months of follow-up, the number of remaining cancer cells declined in 13 patients, 12 of whom reached their lowest levels of residual cancer cells. In seven patients, CML became completely undetectable. Because the study was conducted in a limited number of patients and not compared with other therapies, the researchers warn they cannot be sure that the responses were a result of the vaccine.

"We want to get rid of every last cancer cell in the body, and using cancer vaccines may be a good way to mop up residual disease," says Hyam Levitsky, M.D., professor of oncology, medicine and urology at the Johns Hopkins Kimmel Cancer Center. More research to confirm and expand the results is needed, Levitsky said.

The investigators will be testing blood samples taken from the study patients to identify the precise antigens that the immune system is recognizing. With this information, they will tailor their vaccine for additional studies that monitor immune response more precisely.

Patients receiving the trial vaccine experienced relatively few side effects that included injection site pain and swelling, occasional muscle aches and mild fevers.

According to the investigators, most patients with CML will need to remain on Gleevec therapy for the rest of their lives. More than 90 percent of them will achieve remission, but about 10 to 15 percent of patients cannot tolerate the drug long term. "Often patients have low blood cell counts, fluid retention, significant nausea and other gastrointestinal problems," says B. Douglas Smith, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center. Secondary therapies, including dasatinib and nilotinib, also have many side effects.

Another common side effect of Gleevec, says Smith, is fatigue. "Patients often tell me that they feel about 80 to 90 percent of what they should, and over time, this may have a big impact on their quality of life," he says.

Gleevec also cannot be taken during pregnancy, and since one-third of CML patients are in their 20s and 30s, many patients hoping to start families would like to discontinue taking it.

"Ultimately, should this vaccine approach prove to be successful, the ability to get patients off lifelong Gleevec therapy would be a significant advance," says Levitsky.

The research was funded by the National Institutes of Health.


(Poonam Singhal -- sub-editor compiled and published Vaccine may cure chronic myeloid leukemia CML at HealthNewsTrack on January 11, 2010 sourced from Johns Hopkins Medical Institutions - http://www.hopkinsmedicine.org/)

Leukemia - recent articles and current news stories:

- Umbilical cord blood to treat leukemia
- Early stem cell transplant best for acute myeloid leukemia patients
- Green tea shows promise in leukemia
- Leukemia treatment developed in Australia

Most related articles:

- Vaccine may cure chronic myeloid leukemia CML
- Understanding chronic myeloid leukemia - 10.3
- Gleevec improves special leukemia in children - 8.1
- Green tea shows promise in leukemia - 6.4
- Early stem cell transplant best for acute myeloid leukemia patients - 5.9

More related articles:

- Vaccine, Chronic myeloid leukemia, CML, Imatinib mesylate, Gleevec, Cancer, Leukemia, Anemia, Impaired blood clotting
- Gleevec improves special leukemia in children - 19.6
- Understanding chronic myeloid leukemia - 14.5
- Nplate bone marrow stimulator approved to treat low platelet counts - 11
- Green tea shows promise in leukemia - 10.2

Leukemia related articles:

- Green tea shows promise in leukemia - 4.1
- Gleevec improves special leukemia in children - 4
- Grape seed extract may cure leukemia - 3.8
- Hannah Jones refused heart transplant surgery - 3.7
- Chemotherapy target found for leukemia - 3.6

Leukemia article/news source:

Read more health articles from Johns Hopkins Medical Institutions and health articles from USA.

Leukemia - search related terms:

Anemia, CML, Cancer, Chronic myeloid leukemia, Gleevec, Imatinib mesylate, Impaired blood clotting, Leukemia, Vaccine,
Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (189)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (86)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)


Current news
Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind -- Team cautions that results are very preliminary and they cannot yet rule out other reasons for success

What is Leukemia?
About Leukemia -- Leukemia is a neoplastic diseases of the bone marrow in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, liver, and spleen.


List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015 HealthNewstrack.com
Health Newstrack - Track Health News Daily at HealthNewstrack.com. Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.
0.27